Changing the enzalutamide form from a capsule to a tablet improves the adherence of medicine intake: A case of a significant decrease in the prostate-specific antigen level and improvement in radiographic findings.

dosage form enzalutamide enzalutamide capsule enzalutamide tablet

Journal

IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958

Informations de publication

Date de publication:
May 2019
Historique:
received: 28 11 2018
accepted: 02 03 2019
entrez: 4 8 2020
pubmed: 18 3 2019
medline: 18 3 2019
Statut: epublish

Résumé

In June 2018, enzalutamide began to be sold in a tablet form in Japan and Germany. We herein report the case of an improvement in prostate cancer progression due to changing enzalutamide dosage form from a capsule to a tablet. A 76-year-old man was initially referred to our hospital for the further examination of his elevated prostate-specific antigen level (3664.0 ng/mL). He had developed castration-resistant prostate cancer 10 months after initial treatment. Treatment with enzalutamide (capsule form) was subsequently initiated. In June 2018, drug form of enzalutamide was changed from a capsule to a tablet. After switching to an enzalutamide tablet, his prostate-specific antigen level decreased significantly from 493.0 to 26.5 ng/mL. While the reason for this prostate-specific antigen response is unclear, changing the enzalutamide form from a capsule to a tablet may have improved the adherence of drug intake and thereby resulted in castration-resistant prostate cancer control.

Identifiants

pubmed: 32743396
doi: 10.1002/iju5.12062
pii: IJU512062
pmc: PMC7292163
doi:

Types de publication

Case Reports

Langues

eng

Pagination

143-145

Informations de copyright

© 2019 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

J Smooth Muscle Res. 1996 Apr;32(2):43-50
pubmed: 8845565
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Crit Care Nurs Clin North Am. 1996 Mar;8(1):79-89
pubmed: 8695038
Br Med J (Clin Res Ed). 1982 Dec 11;285(6356):1717-9
pubmed: 6816343
Biol Pharm Bull. 2011;34(11):1765-8
pubmed: 22040893
J Pharm Sci. 1982 Sep;71(9):975-7
pubmed: 7131280
Spec Care Dentist. 1996 May-Jun;16(3):95-103
pubmed: 9084322
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553

Auteurs

Takashi Kawahara (T)

Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan.
Department of Urology Yokohama City University Graduate School of Medicine Yokohama Japan.

Sahoko Ninomiya (S)

Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan.

Yasuhide Miyoshi (Y)

Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan.

Masahiro Yao (M)

Department of Urology Yokohama City University Graduate School of Medicine Yokohama Japan.

Hiroji Uemura (H)

Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan.

Classifications MeSH